Boryung Corporation (KRX:003850)
South Korea
· Delayed Price · Currency is KRW 9,030.00
-10.00 (-0.11%)
At close: Dec 5, 2025
Boryung Revenue
Boryung had revenue of 280.01B KRW in the quarter ending September 30, 2025, with 3.31% growth. This brings the company's revenue in the last twelve months to 1.03T, up 3.79% year-over-year. In the year 2024, Boryung had annual revenue of 1.02T with 18.32% growth.
Revenue (ttm)
1,028.99B
Revenue Growth
+3.79%
P/S Ratio
0.74
Revenue / Employee
671.23M
Employees
1,027
Market Cap
762.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,017.11B | 157.48B | 18.32% |
| Dec 31, 2023 | 859.63B | 99.15B | 13.04% |
| Dec 31, 2022 | 760.48B | 133.20B | 21.23% |
| Dec 31, 2021 | 627.28B | 65.41B | 11.64% |
| Dec 31, 2020 | 561.87B | 37.60B | 7.17% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |